We are a research-driven company that specialises in the development, manufacture and supply of a broad range of High Potency Oral Solid Dose (OSD) Human & Veterinary speciality products.
Since 2006, we have built a reputation as an innovative company specialising in developing and manufacturing of film-coated tablets, soft-gel capsules, and powder or liquid-filled hard-shell capsules.
Our work, which focused on successfully producing cancer chemotherapy drugs, allowed us to create strong partnerships with leading pharmaceutical companies, thus making our founders’ vision a reality. In 2015, our successful track record and reputation for industry excellence prompted the acquisition of Eirgen Pharma by the OPKO Health family of companies.
Becoming a part of OPKO Health has allowed Eirgen Pharma to invest further in our facilities and our people, increasing development and manufacturing capabilities. Eirgen now serves patients in more than 60 countries worldwide, including major markets such as the USA, Europe, Japan, Canada, Australia, the Middle East and Africa.
Nowadays, at Eirgen Pharma’s centre of excellence in Waterford, Ireland, we simplify the journey of getting your product to market by providing full turnkey CDMO services for the development, manufacture and packaging of high potency oral dose medicines for both human and veterinary use. Eirgen also holds the production rights for numerous OSD products and has the capacity to manufacture each of these products at scale.
high potency pharmaceutical products, oncology, cytotoxic products, ema, fda, pmda approved facility, high containment product development, manufacture, sterile fill finish, microbiology, global supply chain, research, development